BerGenBio to present at DNB Nordic Healthcare Conference 2021
Bergen, Norway, 14 December 2021 – BerGenBio ASA (OSE:BGBIO), BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, is pleased to announce that it will be presenting at the 12th DNB Nordic Healthcare Conference on 16th December 2021. The presentation will take place from 11:35 CET and will be made available on the Company website: www.bergenbio.com/investors/presentations/ -End- Contacts Martin Olin CEO, BerGenBio ASA ir@bergenbio.com Rune Skeie, CFO, BerGenBio